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Abstract. Significant progress has been made over the past 25 years in the development of in 
vitro-engineered substitutes that mimic human skin, either to be used as grafts for the 
replacement of lost skin, or for the establishment of in vitro human skin models. In this sense, 
laboratory-grown skin substitutes containing dermal and epidermal components offer a 
promising approach to skin engineering. In particular, a human plasma-based bilayered skin 
generated by our group, has been applied successfully to treat burns as well as traumatic and 
surgical wounds in a large number of patients in Spain.  There are some aspects requiring 
improvements in the production process of this skin; for example, the relatively long time (three 
weeks) needed to produce the surface required to cover an extensive burn or a large wound, 
and the necessity to automatize and standardize a process currently performed manually. 3D 
bioprinting has emerged as a flexible tool in regenerative medicine and it provides a platform 
to address these challenges. In the present study, we have used this technique to print a human 
bilayered skin using bioinks containing human plasma as well as primary human fibroblasts 
and keratinocytes that were obtained from skin biopsies. We were able to generate 100 cm2, a 
standard P100 tissue culture plate, of printed skin in less than 35 minutes (including the 30 
minutes required for fibrin gelation). 
We have analyzed the structure and function of the printed skin using histological and 
immunohistochemical methods, both in 3D in vitro cultures and after long-term transplantation 
to immunodeficient mice. In both cases, the generated skin was very similar to human skin and, 
furthermore, it was indistinguishable from bilayered dermo-epidermal equivalents, handmade 
in our laboratories. These results demonstrate that 3D bioprinting is a suitable technology to 
generate bioengineered skin for therapeutical and industrial applications in an automatized 
manner. 
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1. Introduction 
 
Skin injuries caused by burns, chronic ulcers from different etiology, infections, cancer 
surgery, and other genetic and somatic diseases require effective treatment to prevent morbidity 
or mortality. The World Health Organization (WHO) estimates that nearly 11 million burn 
injuries per year worldwide require medical attention, with approximately 265,000 leading to 
death [1]. To restore the function of the skin after damage and to facilitate wound-healing, 
autologous grafts (autografts) obtained from own-patients donor sites are commonly used to 
repair the skin, while avoiding immune-rejection. Unfortunately, the availability of autografts 
for wound coverage is insufficient when dealing with large and/or severe wounds [2-4]. As a 
result, several approaches have been explored for skin replacement therapy, such as cultured 
autologous epithelial autografts (CEA) (for a review see [5]), but their results are far from ideal, 
since they are limited by their fragility and the difficulty of handling, unpredictable take rate 
and sensitivity to mechanical shearing forces for at least two months post grafting [6-8]. In 
response to these limitations, new approaches for skin engineering have been tested and 
developed in recent years. These advances have led to the development of more sophisticated 
laboratory-grown skin substitutes which contain dermal and epidermal components that 
interact dynamically with each other during in vitro maturation and also after transplantation 
[9-12]. In particular, fibrinogen (and its derivative fibrin) is a blood component that has been 
used extensively as a stromal substitute to construct human skin since it has the advantages of 
low price, availability, and good tolerance to cells; in addition,   if required, it can be produced 
as an autologous scaffold [13-15]. In this context, a human plasma-derived bilayered (including 
dermis and epidermis) skin model was generated by our group and applied successfully to treat 
burns and traumatic and surgical wounds [16, 17].  
The limitations of the current process: high production costs, the need for specialized 
personnel, and the time required for production of a surface of therapeutically useful skin (3-4 
weeks to generate 1 m2), combined with a foreseen higher demand for artificial skin, have all 
led to an increasing need to develop new methods that offer automation, standardization, and 
reduction in time and production costs [7, 18, 19]. Three-dimension al (3D) bioprinting, has 
emerged as a flexible tool in regenerative medicine and provides a platform to address these 
needs. 3D bioprinting opens up the possibility of constructing artificial tissues or organs, either 
autologous or allogeneic, by printing cells, soluble factors and biomaterials in a desired pattern 
with the help of high-precision Cartesian robots [20-23].  The most common procedure 
involves printing layers of hydrogel matrix precursors and a posterior crosslinking in order to 
form a scaffold that provides structural support to the cells and other extracellular components 
embedded within it [24-26]. After an in vitro culture period of time, the printed tissue or organ 
construct can potentially be applied to replace the function of the damaged tissue. 
 
Two different bioprinting approaches in vitro and in vivo have been recently explored for the 
production and analysis of skin constructs containing dermal and epidermal components. In 
the first approach [27, 28], the authors used a free-form fabrication (FFF) technique to deposit 
a variable number of layers of crosslinked collagen and collagen containing either human 
fibroblasts or keratinocytes. In the second approach [29,30], laser assisted bioprinting (LaBP)  
was used to deposit alternating layers, composed of 20 sublayers each, containing immortal 
murine fibroblasts (NIH-3T3) and human keratinocytes (HaCaT cells) embedded in a collagen 
matrix. 
These approaches are mainly aimed at demonstrating the feasibility of generating artificial skin 
by bioprinting. However, in our opinion, they present several drawbacks: 1) In general, they 
do not use human primary fibroblasts and keratinocytes simultaneously. The used cells might 
be less sensitive to the stresses of the bioprinting process, and their proliferation and 
differentiation characteristics are from those of the cells contained in human native skin. 2) The 
printed layered structures are not reminiscent of normal skin and the skin constructs produced 
did not possess the structural quality of the normal human skin. Moreover, the time required in 
these multi-layered deposition methods is currently far from allowing the effective generation 
of the relatively large skin surfaces needed in wound treatment. 
 
To overcome these limitations, in this study we have used a FFF 3D bioprinting technique to 
engineer a human plasma-derived bilayered skin using human fibroblasts (hFB) and 
keratinocytes (hKC) obtained from skin biopsies. The printed human skin was analysed both 
in 3D in vitro cultures and in vivo upon grafting to immunodeficient athymic mice (skin-
humanized mice), using histological and immunohistological methods [31-33]. Our results 
showed that the printed skin had mechanical, structural and functional characteristics similar 
to those of normal human skin, and skin equivalents produced manually in our group. We also 
demonstrated the capacity of our process to reproducibly print large areas of human skin, useful 
for the treatment of diverse cutaneous pathologies such as burns, ulcers and surgical wounds. 
 
 
2. Materials and methods 
 
2.1. Bioprinter design and set-up 
 
The model used in this work was the Printrbot, modified in order to deposit cell-laden 
hydrogels (Fig. 1). Original Printrbot belongs to the open source community and was designed 
by Brook Drumm in 2011. Most of the structural parts were generated by a normal 3D printer 
in ABS (Acrylonitrile-Butadiene-Styrene). The building instructions can be accessed on the 
official Printrbot web page.  
 
As seen in Figure 2 an external module (extrusion module) composed of four perfusion pumps 
and four sterile disposable plastic syringes was designed to contain and extrude the hydrogel 
precursors and the cell suspensions. The plastic syringes and the sterile connecting tubes were 
replaced between experiments to avoid contamination. The content of each syringe will be 
described in section 2.3. These tubes converged at the head into a trifurcated connector where 
their contents were mixed; then, the mixture went through a luer 1.2x40 mm extrusion needle 
without a bevel, acting as “nozzle”. Each syringe was driven by one of the perfusion pumps 
and controlled by an electric stepper motor (NEMA17). The flow of each syringe was directly 
proportional to its volume content in order to obtain a constant homogeneous mixture in the 
extrusion needle. Typically the extrusion flow was 12 ml/min. 
 
The x-y plane contained a heated surface to maintain the temperature at 37oC (Fig 1). The 
printer and the extrusion module were placed in a cell culture laminar flow hood; all the parts 
were sterilized with UV light in the hood. 
 
 
 
 
                                         
 
                                
Figure 1. Bioprinter setup and components. Human plasma, cells and calcium chloride (CaCl2) 
pass through sterile tubes from the extrusion module (E) and they are mixed in the trifurcated 
connector of the head (A). The needle extruder (B) deposits the mixture of components on the 
printing plastic dish (P100, Corning 100 x 20 mm). The heated bed (C) maintains the 
temperature at 37oC. The system is controlled by the control unit (D), which is composed of an 
Arduino board with an ATmega microcontroller and the shield RAMPS 1.4, and a LCD. 
 
 
The printer firmware was installed in the microcontroller (ATmega2560) of a RepRap Arduino 
Mega Pololu Shield (RAMPS), and it manages the mechanical sensors and actuators as well as 
the thermal control of the heated bed. The selected firmware was Marlin, also open source, 
because it is able to control more than one extruder or dispenser motor. Deposition trajectories 
were generated and sent to the RAMPS using Repetier v0.53. This program transformed the 
geometric data into paths or spatial coordinates to be followed by the printer head. It also 
controlled which of the dispensers should be active and the operative procedure time. A script 
in C++ was developed to establish the volume of liquid to be deposited.  
 
Liquids were pumped by a module composed of four separated dispensers, as previously 
described. Each of them had its own syringe (5 or 20 ml) and an electronic stepper motor. The 
motors, NEMA17, presented a resolution of 1.8 degrees step/4.8 kg/cm, and were controlled 
by a DRV8825 driver that provides six different step resolutions (full-step, half-step, 1/4-step, 
1/8-step, 1/16-step, and 1/32-step). The final resolution of the deposition depended on this 
parameter and it could be easily tuned with jumpers. All these drivers, sensors and actuators 
were connected to the RAMPS 1.4 shield, which was mounted over an Arduino Mega 2560 
board that contained a microcontroller ATmega2560. 
 
 
 
2.2. Primary human keratinocyte and human fibroblast culture 
 
Human fibroblasts (hFB) and keratinocytes (hKC) obtained from skin biopsies of healthy 
donors were obtained from the collections of biological samples of human origin; these samples 
are registered in the “Registro Nacional de Biobancos para Investigación Biomédica del 
Instituto de Salud Carlos III”. hKC were cultured following previously described methods [34] 
as modified by our laboratory [15, 35]. The growing media for hKC was a 3:1 mixture of 
Dulbecco's Modified Eagle Medium (DMEM) (GIBCO-BRL) and HAM'S F12 (GIBCO-BRL) 
(hKC medium) containing 10% of fetal bovine serum (FBS), 0.1 nM choleric toxin, 2 nM T3, 
5 mg /ml insulin, 0.4 mg/ml hydrocortisone and 10 ng/ml EGF (Sigma, St Louis, MO). hFB 
were cultured in Dulbecco's modified Eagle's medium (DMEM, Biochrom KG) containing 
10% FBS. 
 
2.3. Preparation and printing of fibrin-based skin 
 
Skin substitutes formed by two layers, representing the dermis (lower layer) and the epidermis 
(upper layer), were generated following the method developed in [15, 17]. The lower layer was 
a plasma-derived fibrin matrix populated with hFB (dermal component) and the upper layer 
was formed by hKC, seeded on the top of the fibrin scaffold (epidermal component). Fresh 
frozen human plasma was provided by a local blood bank (Banco de Sangre del Centro 
Comunitario de Transfusión del Principado de Asturias (CCST) Spain) and was obtained 
according to the standards of the American Association of Blood Banks [36]. The fibrin matrix 
was prepared as previously described in [15, 17] with some modifications required for the 
bioprinting process, as described below. 
 
To generate a dermal substitute, 7x104 cultured hFB were resuspended in 4 ml of DMEM and 
loaded in the first syringe. In the second syringe, a volume of human plasma containing 30 mg 
of fibrinogen (typically 13 ml) was mixed with 200 μl of tranexamic acid (antifibrinolytic agent 
Amchafibrin, Fides- Ecopharma). Finally, in a third syringe 2.3 ml of CaCl2 (prepared at 1% 
w/v in saline, (NaCl 0.9 % w/v)) was loaded. The function of CaCl2 is to induce the coagulation 
of the plasma fibrinogen into a fibrin hydrogel. The total volume of the three syringes was 
adjusted to 25 ml by adding saline to the third syringe. After this, the syringes were put into 
the extrusion module of the bioprinter and their content was mixed (as described in section 2.1) 
and deposited on a P100 tissue culture plate (Corning 100x20mm).  
 
 Printed dermal substitutes were left in a cell culture incubator (at 37oC in 5% CO2) for thirty  
minutes to allow them to polymerize, and then 10 ml of hKC medium, containing 6x106 hKC 
per P100 plate were loaded into the fourth syringe of the extrusion system and deposited over 
the dermal equivalent. hKC were allowed to attach and spread overnight in a cell culture 
incubator. This number was established in order to generate a confluent hKC monolayer at this 
moment. Afterwards, the printed skin equivalents were transplanted on to the backs of 
immunodeficient mice (see section 2.5). 
 
Alternatively, skin substitutes were printed on transwell inserts. The components were placed 
on polycarbonate transwell inserts (1 μm pore) in a 6-well culture plate (Corning Costar Corp., 
Cambridge, MA, 4.15 cm2) for the 3D in vitro assays (see section 2.5). In this case, the 
deposition volume and the trajectories were adjusted to the geometry of these plates. After the 
hKC attaching and spreading step, hKC were allowed to differentiate at the air-liquid interface 
and formed a multilayered skin as explained in section 2.5 
 
                      
 
          
 
Figure 2. Scheme of the bioprinting process. The extrusion module contained four syringes, 
loaded with hFB (a), plasma (b), CaCl2 (c) and hKC (d), respectively. The contents of the 
syringes A, B and C were continuously pumped out at the appropriate speed, mixed as they 
arrived at  the head, extruded through the needle and deposited on the corresponding plate type 
(P100 or transwell), following the trajectories dictated by the control unit. This mixture was 
allowed to polymerize for 30 minutes at 37oC to form a fibroblast-containing fibrin hydrogel, 
which became the dermal compartment of the skin equivalent. Afterwards, the hKC suspension 
contained in syringe (d) was similarly deposited on top of this hydrogel to form a confluent 
monolayer. (A) Equivalents printed on transwell inserts were allowed to differentiate at the air-
liquid surface for 17 days and then analysed. (B) Equivalents printed on P100 plates were 
grafted on to the backs of immunodeficient mice for eight weeks and then analysed. 
 
 
 
 
2.4. Immunodeficient mice 
 
Immunodeficient athymic nude mice were purchased from IFFA- Credo-Charles River (St. 
Aulin-les-Elbeuf, France) and kept and used at the CIEMAT Animal Facility (Spanish 
registration number 28079-21 A) under sterile conditions.  The animals were housed in 
individually ventilated type II cages, a maximum of four  mice to each cage with 25 air changes 
per hour and 10 KGy gamma irradiated soft wood pellets as bedding. Experiments were carried 
out according to European and Spanish laws and regulations. 
 
2.5. In vivo and in vitro maturation and differentiation of printed skin equivalents 
 
As explained in section 2.3, the printing process was designed to produce a fibroblast-
containing fibrin hydrogel covered with a monolayer of hKC. In vivo and in vitro assays were 
performed to analyse the viability of these constructs and their capacity to generate a terminally 
differentiated skin. 
 
For the in vivo assays, once hKCs were attached to the fibrin surface, the cultured equivalents 
were manually detached from the P100 plate and grafted on to the backs of immunodeficient 
mice. Four female mice were aseptically cleansed and grafted as previously described [17].   
Full thickness circular wounds of 12 mm diameter were produced by means of a punch on the 
dorsum of each mouse. Then, circular samples of the same diameter were obtained by the same 
punch from the printed skin substitutes, placed on the generated wounds and covered by the 
skin, previously removed from these mice, devitalized by three cycles of freezing and thawing. 
The devitalized skin was kept in place with the help of sutures. The grafts were analysed eight 
weeks after grafting took place. 
 
For the in vitro assays, skin constructs deposited on transwells were allowed to differentiate at 
the air-liquid interface for 17 days at 37oC in a CO2 incubator in differentiating medium (hKC 
medium containing 0.5% FBS and 50 μM of ascorbic acid). The medium was changed every 
three days [37-39]. 
 
2.6. Histology and immunostaining 
 
Four-mm biopsies of human skin regenerated either in vitro or in vivo were collected with the 
help of a punch. For histological analysis, samples were fixed in 3.7% buffered formaldehyde, 
and embedded in paraffin. Three-μm cross-sections were dewaxed, rehydrated and stained with 
hematoxylin-eosin (H/E).  
 
For immunohistochemistry experiments, the biopsies were frozen and five-μm cryosections 
were analysed using primary specific antibodies against well-known skin markers: anti human-
vimentin (V9, BioGenex, San Ramon, CA to distinguish hFB), antikeratin 5 (polyclonal 
AF138, BabCO, Berkeley, CA; to label hKC of the proliferative basal layer), antikeratin 10 
(monoclonal AE2, ICN Biomedicals, Cleveland, OH; to label suprabasal keratinocytes), and 
antihuman filaggrin (polyclonal AF-62, BabCO; to label the epidermal granular layer). To 
determine the formation of the dermoepidermal basal membrane, a specific antibody against 
human-collagen VII (Clone LH7.2, Sigma) was used. To detect blood vessel formation, 
biopsies from human skin regenerated on nude mice were labelled with anti-SMA (Smooth 
Muscle Actin, C6198, Sigma, St. Louis, USA)). Samples were coverslipped using Mowiol 
(Hoechst, Somerville, NJ) mounting media containing 46-diamidino-2-phenyl indole (DAPI, 
ROCHE, Germany, 20 μg/ml) for nuclei visualization. 
 
 
2.7. Analysis of epidermal cells viability 
 
To determine if the printing process compromised the viability of the epidermal cells, freshly 
trypsinized hKC (as a control) and hKC, pumped through the extrusion system after 
trypsinization, were subjected to Colony-Forming Assay (CFA) as described elsewhere [40, 
41].  
 
In brief, approximately 500 hKC were placed into each well of a six multi-well plate containing 
a feeder layer of lethally irradiated 3T3 cells. Three wells were seeded with control hKC and 
the other three were seeded with extruded hKC. After nine days, cultures were stained with 
fluorescent Rhodamine B (R-6626, Sigma St Louis, USA) to estimate the number of epidermal 
colonies using an inverted fluorescence microscope. The number of colonies was calculated by 
counting ten fields per well. 
 
  
 
3. Results 
 
3.1. Analysis of printed human skin differentiated in vitro 
 
Bioengineered equivalents deposited into transwells were allowed to differentiate at the air-
liquid interface for 17 days. As shown in the histological staining (Fig. 3B), printed equivalents 
generated a tissue with a structure similar to that obtained differentiating handmade skin 
equivalents (Fig 3A) and also similar to normal human skin (Fig 4 C). A well-formed, 
orthokeratotic stratum corneum was present indicating terminal differentiation. The dermal 
compartment contained well spread hFB in the fibrin matrix. To analyze the nature of this 
differentiation more carefully, immunofluorescent analysis was carried out. Expression of 
keratin K10 was detected in suprabasal cells (Fig 3 C), where this intracellular structural protein 
is specifically synthesized in normal skin. To visualize the state and persistence of the hFB, 
after this relatively prolonged culture time, we stained cryosections with a specific antibody 
against human vimentin, a cytoskeletal protein characteristic of this kind of cell. This 
demonstrated the proper growth and spreading of the hFB comprising the dermal compartment 
of the bioprinted skin (Fig. 3D). The lack of strateum corneum in Figures 3C and 3D is due to 
the cryosectioning method which frequently removes these structures.  
 
 
                   
      
 
Figure 3. In vitro 3D human skin equivalents obtained after 17 days of differentiation at the 
air-liquid interface. (A): “Handmade” skin equivalent following our previous protocol. (B)-
(D): Printed skin equivalents. (A), (B): Histological analysis of fixed samples, using 
Hematoxilyn-Eosin. (C), (D): Immunostaining of frozen samples using an anti-K10 antibody 
(C, green immunofluorescence) and an anti-human vimentin antibody (D), red 
immunofluorescence). Blue color in (C) and (D, denotes DAPI staining of the nuclei. E and D 
in (A), (B), (C) and (D) denote the epidermal and the dermal compartments, respectively. The 
white dotted line indicates the dermo-epidermal junction (basal membrane). Scale bar: 100 μm. 
 
 
3.2. Analysis of printed human skin differentiated in vivo 
 
To study if bioprinted skin substitutes had the capacity to differentiate between in vivo and a 
genuine skin, we grafted them on to the back of immunodeficient athymic mice. These grafts 
were performed orthotopically, so that the printed equivalents were placed on the wound beds 
generated on the back of the immunodeficient mice, as described in [17, 35] (see also section 
2.5). Between four and six weeks after grafting, the devitalized mouse skin, used as a biologic 
bandage, fell off and the grafted human skin became visible (Fig. 4A). It exhibited a 
characteristic wrinkled, thick and whitish aspect, very similar to the appearance of native 
human skin and clearly different from the surrounding thin and pinkish mouse skin. 
Histological analysis demonstrated that the regenerated human skin presented a structure very 
similar to that of normal human skin (compare Fig. 4B with Fig 4C). All the strata characteristic 
of normal skin, stratum basale, stratum spinosum, stratum granulosum and a well-developed 
stratum corneum are easily identified in the printed skin. 
 
                
  
 
 
Figure 4. Histological analysis (8 weeks postgrafting) of bioprinted human skin grafted to 
immunodeficient mice. (A) Visual appearance of the grafted human skin. E and D in (B) and 
(C) denote the epidermal and the dermal compartments, respectively. The dotted line marks the 
boundary between human and mouse skin. (B) H/E staining of the regenerated human skin. (C) 
H/E staining of normal human skin. The white dotted line in B and C indicates the dermo-
epidermal junction (basal membrane).  Scale bar: 100 μm. 
 
 A more detailed analysis of the original printed skin was performed by immunofluorescence 
using well-established skin markers. Accordinlgy, the basal proliferative stratum was clearly 
revealed by labelling with an antibody recognizing keratin K5 (Fig. 5A, green staining). The 
correct formation of the dermo-epidermal junction of the skin was confirmed by labelling with 
an antibody against human collagen VII (Fig. 4B green staining), the protein forming the 
anchoring fibrils that bind together epidermis and dermis. This structure is very important for 
the mechanical stability of the skin; its lack leads to severe blistering due to the separation of 
the two compartments of the tissue, observed in patients suffering from Dysthrophic 
Epidermolysis Bullosa (DEB) [42]. We consider the presence of the basal lamina and the 
stratum corneum as clear indications of proper and complete differentiation of the grafted 
printed skin. As in normal mature skin, there was a strong suprabasal expression of keratin K10 
(Fig. 5C, red staining) and of the late differentiation marker filaggrin, characteristic of the 
granular layer (Fig.5D, green staining). Also rete ridges (a hallmark of mature human skin, not 
found in mouse skin) were detected in some regions of the grafted printed skin (asterisks in 
Fig.5D.) 
 
In addition, immunostaining with a specific antibody against human vimentin, showed the 
persistence of hFB exclusively in the dermal compartment of the regenerated skin (Fig. 5B, red 
staining). Another important parameter to assess in the regeneration process is the 
vascularization of the grafted human skin, which allows oxygenation and nutrition of the new 
tissue and therefore, its long-term persistence. As shown by the red staining and arrows in 
Figure 5D, blood vessels (SMA +, red) were detected in the dermis of the printed skin upon in 
vivo regeneration. 
 
 
                
   
Fig 5. Immunohistochemical analysis (eight weeks postgrafting) of bioprinted human skin 
grafted to immunodeficient mice using antibodies against skin markers. (A) Keratin K5 
detection (green immunofluorescence). (B) Collagen VII (green line between dermis and 
epidermis) and vimentin (the red colour in the dermal compartment) detection. (C) Human 
keratin K10 detection (red suprabasal staining: notice that the basal layer is negative). (D) 
Filaggrin (green staining in the stratum granulosum) and SMA (red staining) detection. Arrows 
point to some of the capillaries present in the dermal compartment. Nuclei were stained with 
DAPI (blue). The white dotted line in panels A and C, indicates the epidermal-dermal 
boundary. Inside the images: Ep- Epidermal compartment, Dr- Dermal compartment. Scale 
bar: 100 μm. 
 
 
 
 
3.3. hKCs survival analysis 
 
 
hKC are more delicate and difficult to keep in culture than fibroblasts. In particular, it is well- 
established that hKC differentiate terminally when cultured in suspension [43]. Therefore, it is 
necessary to analyze the viability of these cells after going through the bioprinting process. To 
do this, we performed colony-forming efficiency (CFE) assays as described in materials and 
methods (section 2.7). We found (Fig. 6) that the number and the size of the colonies were very 
similar, both before and after the cells underwent the bioprinting process (the same number of 
cells were seeded in both cases). 
 
 
                 
 
Figure 6. Colony-forming efficiency assay. Microscopic appearance (phase contrast) of the 
hKC colonies grown in the presence of a feeder layer of lethally irradiated 3T3 cells; before 
(A) and after (B), passing them through the printing system. (C) Number of keratinocyte 
colonies per microscopic field before (left) and after (right). Scale bar: 200 μm. 
  
 
4. Discussion 
 
This work shows the automation and production of printed human skin containing dermal and 
epidermal components, with structural and functional properties similar to those of skin 
constructed by conventional manual procedures developed previously in our group, and also to 
those of in vivo human skin. Due to the relatively simple structure of skin tissue and the strong 
clinical relevance of methods facilitating the treatment of wounds, production of skin tissue 
containing dermal and epidermal components by bioprinting is currently an area of active 
development. To our knowledge, two main approaches containing in vitro and in vivo analysis 
have been published [27-30]. The first approach, which was based on a layer by layer 
deposition technique, demonstrated the feasibility of the multi-layered deposition of fibroblast 
and keratinocytes in a collagen scaffold. The dermal compartment contained eight acellular 
collagen layers, interspersed with three fibroblast-containing collagen layers. On top of this, 
two keratinocytes-containing collagen layers were deposited. This requires that, after 
deposition, the FB migrate to generate a homogeneous distribution throughout the collagen 
matrix, as can be observed in a normal dermis.  
 
Although this layer deposition, as proposed by the authors, could prevent the contraction of the 
collagen hydrogel during the submerged cultured period, other authors have reported that 
collagen matrix contraction is a measure of the capacity of the fibroblasts to support the 
organization and growth of human skin equivalents [44]. In addition, this method presents an 
anomalous severe shrinking and compaction of the dermal compartment during the air-liquid 
culture, the step in which keratinocyte stratification and differentiation to form an epidermis 
takes place.  
 
Apart from this, it is difficult to evaluate the quality of the 3D skin obtained, since the authors 
do not show the localization of any of the several well-known skin differentiation markers. In 
addition, the histology of the skin tissues does not show proper stratification and terminal 
differentiation as compared to human skin. As the authors recognize, this can be, at least in 
part, due to the use of an immortalized keratinocyte cell line (HaCat cells) instead of primary 
hKC. Finally, based on the data provided by the authors, the estimated printing speed allows 
the deposition of 1 cm2 skin per hour which is a very slow process considering the large 
surfaces needed for clinical or commercial applications.  
 
The second approach used a laser assisted bioprinting technique (LaBP) to arrange immortal 
human HaCat and mouse NIH-3T3 fibroblast, in order to create 3D constructs structurally 
similar to native skin. In this technique, 20 collagen sublayers containing FB were printed onto 
a sheet of MatridermTM and subsequently 20 collagen sublayers containing KC were printed 
on top of it. The 3D-bilayered cell constructs were kept for 10 days under submerged culture 
conditions and either cultured for 11 days at the air-liquid interface, or grafted for 10 days to 
the back of mice using the dorsal skin fold chamber method [30]. A clear problem of this 
method that complicates the interpretation of the results and, therefore, its applicability, is the 
use of immortalized keratinocyte and fibroblast cell lines; in particular the NIH-3T3 murine 
fibroblasts that are very different from hFB. Moreover, the histological and 
immunohistochemical data presented by the authors indicated some relevant differences when 
comparing their printed skin with normal human skin: 1) From the histological point of view, 
it is apparent that in the histological sections of the in vivo implants using the dorsal skin full 
chambers, the human epidermis, although well differentiated as indicated by the presence of a 
stratum corneum, is clearly thinner than the mouse epidermis. It is known that human skin is 
thicker than mouse skin, in particular in experiments where human skin equivalents are grafted 
onto the back of the mice. (35, 17). 2) From the immunohistochemical point of view, K14 is a 
well-established marker of epidermal basal cells as reported by the authors in normal mouse 
skin. However, this marker is found in all the epidermal layers of both in vivo and in vitro 
differentiated printed skin. Similarly, Ki67, which is a marker of cell proliferation that is also 
restricted to basal cells, was found evenly distributed through the whole epidermis of in vitro 
cultures. In agreement with the authors, we think that the time (11 days at the air-liquid 
interface and 10 days grafted) used in these experiments, due to the limitations imposed by the 
dorsal skin full chamber method, is a too short time to obtain a fully differentiated epidermis. 
Indeed, according to Fusenig and coworkers [45, 46], the group that characterized HaCaT cells, 
these cells need between three and six weeks to develop a fully differentiated epidermis upon 
in vivo transplantation to the back of nude mice.  They are unable to do so in vitro unless very 
specific culture conditions are used, which is not the case in the LaBP experiments. The 
delocalized K14 and Ki67 staining observed in these experiments is also a hallmark of the early 
stages of HaCaT 3D differentiation [45, 46]. Although it is difficult to make an accurate 
estimation from the data provided by the authors, a caveat concerning this technology is what 
would be the time required to produce a skin surface of clinical or commercial interest (50-100 
cm2).  
 
 Therefore, to fully validate the bioprinting method for the production of a tissue with structural 
and functional properties, similar to normal human skin,   the use of human primary FB and 
KC is necessary. According to this, we used primary human cells together with a fibrin-based 
dermal matrix previously developed by our group for the production of large skin surfaces, 
useful in the treatment of severe and extensive burns, wounds with loss of substance and skin 
fragility diseases [16, 17]. Based on the foregoing, we developed an extrusion bioprinting 
method that did not harm these biological components, in particular, hKC, which are known to 
terminally differentiate when they are kept in suspension [43]. Firstly, we analysed in vitro the 
printed skin equivalent, using H/E staining and differentiation markers to confirm that the 
generated skin had  correct architecture (Fig. 3B and 3D) and differentiation (Fig. 3C). 
Secondly, the structure and functionality of the printed human skin was further analysed on 
skin-humanized mice. This model recapitulates faithfully the characteristics of the skin from 
which human cells were obtained (donor’s skin). Our laboratory has extensive experience, and 
uses it to model diverse cutaneous diseases [31] and processes [47, 48]. To our knowledge, it 
constitutes the best system to perform long-term experiments with human skin in an in vivo 
scenario. We used H/E staining (Fig 4) and several differentiation markers such as keratin 5 (a 
marker of proliferative basal keratinocytes), human vimentin (a marker of human fibroblasts), 
human-collagen type VII (a marker of dermoepidermal basal membrane), keratin 10 (a marker 
of suprabasal differentiated keratinocytes) and human-filaggrin (a marker of keratinocyte 
terminal differentiation) (Fig 5). These markers labelled the same cells and structures in the 
bioprinted skin as they do in human normal skin, including the presence of a well-developed 
stratum corneum and a basal membrane. In addition, it is important to highlight the in vivo 
formation of rete ridges, a hallmark of mature human skin, not found in mouse skin and so far, 
not reported with printed human skin.  
 
 
Neoangiogenesis formation is one of the most crucial events for successful skin grafting to take 
place. Obviously, this is particularly relevant if one considers the clinical applications of 
bioengineered skin equivalents. As shown in Fig 5D, and also reported in [30], small blood 
vessels were found in the grafted bioprinted equivalents beneath the epidermis. They are similar 
to the capillary network found in the papillary dermis of normal skin, which is critical for 
nourishing the avascular epidermis. These blood vessels seem to grow in from the depth of the 
wound bed into the dermal compartment. This is also observed in patients with grafted skin 
and it is attributed to endothelial growth factors, and other soluble factors, largely produced by 
keratinocytes and fibroblasts; for review see [49]. This finding represents additional evidence 
of the functionality of our skin regenerated from human bioprinted equivalents.  
 
  
We consider that the two approaches discussed above [27-30], are clearly relevant as they 
describe multi-layered deposition techniques for skin bioprinting. Together with our work, they 
demonstrate that different bioprinters and bioprinting technologies can be potentially used to 
produce human skin. Clearly, the design of appropriate bioinks is a critical step for the 
production of printed skin with structure and functionality increasingly similar to normal 
human skin.  Based on our previous experience of treating patients with skin equivalents, we 
have developed a simple, flexible and robust method to produce human skin which is useful in 
the clinic (e.g. for treatment of skin wounds) and in industry (e.g. for drug screening). Our 
approach allows the deposition of 100 cm2 of human skin in less than 35 minutes, which is 
much faster than approaches reported in the literature [27-30].  
 
In addition, other bioprinting approaches use collagen as a three-dimensional matrix, a 
biomaterial commonly used in the production of dermo-epidermal equivalents that, in our 
opinion, presents two main disadvantages when compared to the human plasma-based dermal 
scaffolds used in this work. Firstly, human plasma, unlike animal renatured collagen, provides 
a more suitable three-dimensional scaffold to promote migration, proliferation and 
differentiation of the cells in the wound bed [15, 17, 50]. Secondly, human plasma-based 
scaffolds allow efficient production of collagen by hFB and the concomitant remodelling of 
the scaffold to generate a dermal extracellular matrix similar to that found in normal human 
skin [15, 17]. 
 
 
5. Conclusions 
 
We have developed a simple and robust bioprinting method and bioinks that allow the 
production of human bilayer skin, using human plasma and primary human fibroblasts and 
keratinocytes. Based on careful histological and immunohistochemical in vitro and in vivo 
analysis, we demonstrated that the printed skin was very similar to normal human skin and 
indistinguishable from bilayer dermo-epidermal equivalents, previously produced manually in 
our laboratory and successfully used in the clinic. This method allows the production of human 
skin in amounts and times appropriate for its clinical and commercial use. The method also 
opens up the possibility of producing skin equivalents in an automatized and standardized 
manner, which should lead to a reduction in the cost of the product and an improvement in the 
production line, thereby overcoming some of the problems presented by the current manual 
production method. 
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